When is medical industry backing lacking?

A sales representative from Megastint approached Dr A. Krasia with an offer to financially support future educational conferences and allow his institution to be a training center if he participates in a new study comparing an old product to a recently approved and more expensive one. Dr Krasia and his department currently use Megastint's products. The medical center's utilization committee must approve the addition of more expensive pharmaceuticals, devices, or equipment, and Dr Krasia is the chair. How should Dr Krasia respond to Megastint's offer of financial support and to become a training center?